![]() | |
| 公司名 | BOC Sciences |
| 联系人 | Linna Green |
| 电 话 | +16314854226 |
| 手 机 | +16314854226 |
| 电子邮件 | info@bocsci.com |
| 网 址 | http://www.bocsci.com/ |
| 地 区 | 其他 |
| 邮 编 | 11967 |
在线询盘仅适合非紧急采购的情形,您需要留下收货地域,采购数量及联系方式。供应商在收到您的询盘信息后,会通过您留下的联系方式联络您。如果您希望立即和供应商交谈,请直接拨打供应商电话。供应商手机:+16314854226
| 中文名 | KW-2449 |
| 英文名 | (E)-(4-(2-(1H-indazol-3-yl)vinyl)phenyl)(piperazin-1-yl)methanone |
| 别名 | 化合物PF06650833;多靶点激酶抑制剂(KW-2449);[4-[2-(1H-吲唑-3-基)乙烯基]苯基]-1-哌嗪基甲酮 |
| CAS | 1000669-72-6 |
| EINECS | |
| 化学式 | C20H20N4O |
| 分子量 | 332.4 |
| inchi | |
| 包装信息 | 100 mg |
| 价格 | $489 |
| 产品描述 | KW-2449 KW-2449 is a novel multikinase inhibitor, which suppresses the growth of leukemia cells with FLT3 mutations or T315I-mutated BCR/ABL translocation. Recent research showed that HDACIs increase KW-2449 lethality in Bcr/Abl(+) cells in association with inhibition of Bcr/Abl, generation of ROS, and induction of DNA damage. This strategy preferentially targets primary Bcr/Abl(+) hematopoietic cells and exhibits enhanced in vivo activity. Combining KW-2449 with HDACIs warrants attention in IM-resistant Bcr/Abl(+) leukemias. |
| 产品链接 | http://www.bocsci.com/kw-2449-cas-1000669-72-6-item-84-286439.html |
| 更新日期 | 2025-04-30 11:27:47 |